Skip to main content

Payers' Guide

FDA Approvals, Drug Updates, Payers' Guide
Trends in the 2013 Pharmaceutical Pipeline
Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD
Read More
Select Drug Profiles, Payers' Guide
Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs
Lynne Lederman, PhD, Medical Writer
Read More
Select Drug Profiles, Payers' Guide
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
Loretta Fala
Read More
Select Drug Profiles, Payers' Guide
Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
Alice Goodman, Medical Writer
Read More
Select Drug Profiles, Payers' Guide
Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis
Alice Goodman, Medical Writer
Read More
Select Drug Profiles, Payers' Guide
Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm
Loretta Fala
Read More
Select Drug Profiles, Payers' Guide
Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia
Loretta Fala
Read More
Select Drug Profiles, Payers' Guide
Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Loretta Fala
Read More
Select Drug Profiles, Payers' Guide
The Health Burden of Multiple Myeloma: Subcutaneous Velcade a New, Convenient Route of Administration Option
Rhonda Williams, Medical Writer
Read More
Select Drug Profiles, Payers' Guide
Kyprolis: A New Treatment Option for Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent
Lynne Lederman, PhD, Medical Writer
Read More
Page 18 of 19
Results 171 - 180 of 185